Alcon shareholders lambast Novartis' buyout bid
This article was originally published in Clinica
Executive Summary
Drugs giant Novartis has hit a snag in its efforts to gain full ownership of eyecare company Alcon, as it faces ongoing resistance from the latter's shareholders.